Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
← catalyst calendarNCT06899126 · readout in 1,344 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
686estimated
Sites
237
Countries
Argentina, Belgium, Brazil +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-24 | actual | When the study began enrolling |
| Primary completion | 2030-04-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-11-24 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Trastuzumab Deruxtecan — also filed as T-DXd, ENHERTU®, DS-8201a
- Drug: pembrolizumab — also filed as KEYTRUDA®
- Drug: Pemetrexed
- Drug: Platinum Chemotherapy
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival by Blinded Independent Central Review
measured From date of randomization to the date of radiographic disease progression or death due to any cause, up to approximately 54 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed